sterna biologicals prepares for phase IIB clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis

Marburg, Germany, September 05, 2018

  • Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
  • Devices for SB010 in asthma selected, oral formulation work for SB012 in ulcerative colitis (UC) started

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today provided an update on its preparations for phase IIb clinical development of its GATA-3 antagonist drug candidates SB010 and SB012.

sterna biologicals presents detailed results from successful phase 2a study with GATA-3 specific DNAzyme formulation SB012 in patients with ulcerative colitis

Marburg, Germany, June 5, 2018

  • Comprehensive data set presented at Digestive Disease Week® in the U.S.
  • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis
  • Further support of GATA-3 antagonism as promising treatment approach for variety of chronic inflammatory diseases

sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that the full data set from the successful SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with the GATA-3 specific DNAzyme formulation SB012, was presented during an oral session on June 5th at Digestive Disease Week® in Washington, DC.

sterna biologicals announces phase IIa data with SB010 published in Respiratory Research

Marburg, Germany, April 19, 2018

  • Investigator initiated study sponsored and funded by DZL (German Center for Lung Research) in patients with moderate to severe eCOPD
  • Primary endpoint and key secondary endpoints met

Sterna biologicals GmbH & Co. KG (“sterna”), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that data from a randomized, double-blind, placebo-controlled, multicenter phase IIa trial with SB010 in chronic obstructive pulmonary disease (COPD) patients with eosinophilic airway inflammation have been published in the peer-reviewed medical journal, Respiratory Research[i].

sterna biologicals announces data with gata-3 specific dnazyme SB012 to be presented at Digestive Disease Week®

Marburg, Germany, May 29, 2018

  • Further insights and data from Phase 2a trial in ulcerative colitis

Sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that further insights and data from a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its DNAzyme candidate SB012 will be presented at Digestive Disease Week® (DDW) in Washington, DC, June 2-5, 2018.

sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis

Marburg, Germany, February 19, 2018

  • Data presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).
  • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. This represents a further validation of GATA-3-antagonism for the treatment of a variety of chronic inflammatory diseases.

sterna biologicals GmbH & Co. KG ("sterna"), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that positive data from the SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its GATA-3 specific DNAzyme formulation SB012, were presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).